Background: CD44 is a transmembrane receptor for the extracellular matrix glycosaminoglycan, hyaluronan. This receptor-ligand interaction plays an essential role in tumour progression, in embryonic tissue morphogenesis and in leukocyte migration during inflammation. It is well documented that the interaction between CD44 and hyaluronan is strictly regulated, but little is known about the relationship between hyaluronan-dependent cell adhesion and cell migration.
Background
The process by which malignant cells disseminate from a primary tumour to form secondary (metastatic) tumours involves a complex series of changes in cell adhesion and motility. Key steps in this process are: a reduction in adhesion to the neighbouring tumour cells, balanced by increased adhesion to the extracellular matrix; degradation of this matrix; migration through the stroma; entry and exit from the circulation whilst evading immune surveillance; and proliferation in a secondary site. In all of these steps, plasma membrane adhesion/recognition receptors play a crucial role. In recent years, particular interest has focussed on CD44 and its principle ligand, the extracellular matrix glycosaminoglycan, hyaluronan. It has been demonstrated that the interaction between CD44 and hyaluronan can be an essential component of tumour growth and metastasis, as well as of a variety of normal physiological events [1] .
CD44 is an integral membrane glycoprotein comprised of a 37 kDa protein core that is extensively modified by Nand O-linked glycosylation and the variable addition of chondroitin and heparin sulphate side chains. Different forms of CD44 can also be produced by the insertion of combinations of ten alternatively spliced exons into the extracellular domain [2] . It is known that the ability of CD44 to interact with its ligand is subject to a number of regulatory mechanisms, including conformational changes in the extracellular domain and/or clustering of the receptor [3] , insertion of alternatively spliced exons [4] [5] [6] and glycosylation [7, 8] . In addition, there is an 'inside-out' signalling component, in that removal of the highly conserved 70-amino-acid cytoplasmic domain can abrogate binding to hyaluronan [9] [10] [11] [12] . Despite these advances in understanding the control of hyaluronan binding, little is known about the mechanisms that control hyaluronan-mediated cell migration other than that the expression of a hyaluronan-binding form of CD44 is required [5] .
CD44 is subject to phosphorylation by a serine/threonine protein kinase [13, 14] , and mutational analysis has shown that the serine residues at positions 323 (Ser323) and/or 325 (Ser325) are the target residues in human [15] and murine [11] CD44. A range of phosphorylation mutants in which these target serines have been changed in various combinations to aspartic acid, glutamic acid, glycine or alanine have been generated. When expressed in CD44-negative AKR1 T-lymphoma cells, the human wild-type CD44 and all of the CD44 phosphorylation mutants are equally efficient in binding soluble FITC-conjugated hyaluronan, and in mediating cell attachment to a hyaluronan substrate; however, removal of the cytoplasmic domain abrogates the ability of CD44 to bind to hyaluronan [12] . Although it was found that phosphorylation did not play a role in mediating CD44-hyaluronan interactions when CD44 was expressed in AKR1 cells, it was suggested in these studies that, in adherent cell lines, phosphorylation might regulate CD44-dependent migration on a hyaluronan substratum. To investigate this possibility we have chosen to study two cell lines, RPM-MC cells and L cells. The human RPM-MC cell line was derived from a recurrent cutaneous melanoma and has undetectable levels of CD44 expression [16] . In contrast, murine L-cell fibroblasts endogenously express the haematopoietic CD44H isoform. Here we present evidence which suggests that CD44 phosphorylation is critical for migration, but not for adhesion, in both cell types.
Results
The characteristics of binding to soluble hyaluronan by CD44-expressing AKR1 cells has been carefully documented by Perschl et al. [17] . These authors have shown that in clonal transfectants, a threshold of CD44 expression is required before hyaluronan binding is detected, and that above this threshold there is considerable variability in the distribution of hyaluronan binding relative to CD44 expression. Using a similar analysis we have shown that clonal RPM-MC cell lines transfected with a plasmid expressing human CD44 exhibit equivalent binding characteristics (Fig. 1) . Moreover, we found no reproducible differences in hyaluronan binding between wild-type CD44 and two CD44 phosphorylation mutants, in which the target serine residues, Ser323 and Ser325, had been changed to Gly323 and Ala325 (GA CD44) [15] or to Glu323 and Glu325 (EE CD44) [12] .
Given these results it was important to show that the ability of the phosphorylation mutants to bind to soluble Table 1 ) were labelled with FITC-hyaluronan (FITC-HA) and CD44 was labelled with monoclonal antibody E1/2 and detected with phycoerythrin (anti-CD44-PE) as previously described [12] . Table 1 Comparison of independent clonal RPM-MC and L-cell lines expressing CD44 and CD44 phosphorylation mutants.
Cell line
Human CD44 Adhesion (%) Migration (mm) expression hyaluronan reflected an ability to mediate cell adhesion to a hyaluronan-coated substratum, as this is a more physiologically relevant assay.
RPM-MC clones
To this end, we tested a number of independent RPM-MC transfectants in a plate-binding assay; CD44 expression levels were assayed in parallel (Table 1 ). In eight of the nine transfected cell lines, the levels of human CD44 expression were 90-131 % of those found on human F1084 fibroblasts, and all eight showed enhanced adhesion to hyaluronan-coated plates. The exception was the RPM-MC clone GA3, which expressed very low levels of the mutant CD44 protein and bound to hyaluronan at a level only marginally above background.
As shown in Figure 2a , the enhanced binding seen in the representative RPM-MC transfectants (WT1, GA1 and EE1; see Table 1 ) was significantly reduced by pre-incubating the cells with the anti-human CD44 monoclonal antibody E1/2. Of interest is the observation that parental cells and cells transfected with vector alone (neither of which expressed CD44) both adhered more strongly to wells coated with hyaluronan than to BSA-coated control wells, indicating that a hyaluronan receptor other than CD44 is expressed by RPM-MC cells.
These studies were repeated using murine L-cell fibroblasts. These cells were chosen because it was important to assess the behaviour of the mutant CD44 proteins in a separate and distinct cell line, and in the context of an endogenous CD44 background. The L-cell line employed here expresses moderate levels of CD44 (38 % of that detected on Swiss 3T3 fibroblasts), which results exclusively from the expression of the haematopoietic CD44H isoform (data not shown). As shown in Figure 2b , parental L cells bound to hyaluronan-coated wells more efficiently than to BSA-coated control wells. This binding was mediated by endogenous CD44 because binding was reduced to near background levels by pre-incubating the L cells with the anti-mouse CD44 monoclonal antibody KM201. When L cells were transfected with the plasmid expressing human CD44 there was a significant increase in their ability to bind to hyaluronan, and this increase was abrogated if the cells were pre-incubated with the anti-human CD44 antibody, E1/2. A comparison of the binding characteristics of a number of independently isolated transfectants demonstrated that, as with the RPM-MC and AKR1 transfectants, the hyaluronan binding mediated by the CD44 phosphorylation mutants was indistinguishable from that mediated by wild-type CD44 (Table 1 ; Fig. 2b ).
It has previously been shown that, when expressed in RPM-MC cells, wild-type CD44 can promote migration across a hyaluronan-coated substratum; however, neither a non-hyaluronan-binding CD44 splice variant nor a CD44 mutant containing a truncated cytoplasmic domain have this ability [5] . We were interested to determine whether CD44 phosphorylation mutants that were competent to bind hyaluronan were also able to mediate hyaluronandependent cell migration. RPM-MC transfectants were cultured to semi-confluence on hyaluronan or BSA-coated plates, wounds (approximately 1.2 mm wide) were created in the monolayer and wound closure was measured over a 48 hour period. In this assay, transfectants expressing wild-type CD44 displayed a significantly increased migration rate on hyaluronan compared to cells transfected with vector alone; this increased migration was CD44-specific because it was blocked by the E1/2 antibody. Strikingly, cell lines expressing equivalent levels of GA CD44 or EE CD44 only migrated at background levels and this migration was unaffected by the presence of the E1/2 antibody (Figs 3 and 4a) . Interestingly, although the binding of vector-transfected RPM-MC cells to hyaluronan-coated plates was more efficient than the binding to BSA-coated plates (Fig. 2a) , there was no significant difference in cell motility on the two surfaces.
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Figure 2
Cells transfected with plasmids encoding wildtype CD44 or the phosphorylation mutants exhibit enhanced binding to hyaluronan-coated plates. Parental RPM-MC cells and the transfected RPM-MC cell clones Vector1, WT1, GA1 and EE1 (a), or parental L cells and the transfected L-cell clones Vector1, WT1, GA1 and EE1 (b), were detached from tissue culture dishes and allowed to recover for 60 min in Petri dishes in the presence or absence of 400 g ml -1 of the monoclonal antibodies E1/2 or KM201. Cells were then allowed to adhere to hyaluronan-coated wells or bovine serum albumin (BSA)-coated control wells for 30 min at 37°C. After washing, the number of adherent cells was measured by adsorption of crystal violet. Values of 100 % relate to the total number of cells seeded.
Each value represents the mean ± S.E.M of at least three determinations. These results do not reflect abnormalities in the clonal cell lines employed, as a number of independently isolated transfectants gave essentially identical results (Table 1) . Furthermore, similar results were obtained with the L-cell transfectants. We examined a number of independent clonal cell lines and found that the expression of wild-type CD44 led to an increase in hyaluronan-dependent L-cell motility compared to parental cells or to cells transfected with vector alone. This enhanced migration rate was not seen in cells expressing the GA CD44 or EE CD44 phosphorylation mutants (Table 1 ; Fig. 4b ). A noticeable difference between L cells and RPM-MC cells was that L cells transfected with vector alone exhibited an increased migration rate on hyaluronan compared to BSA-coated plates. This difference was a result of the fact that L cells expressed endogenous CD44 because inclusion of the KM201 antibody in the migration assay reduced hyaluronan-dependent migration to levels seen on control plates.
Finally, these results demonstrating that CD44 phosphorylation mutants were unable to mediate hyaluronandependent motility were confirmed using an independent Transwell filter migration assay (Fig. 5) . Expression of wild-type CD44 in both cell lines resulted in a significantly increased rate of migration compared to cells transfected with vector alone; this increase was blocked if the E1/2 antibody was included in the assay. As with the wound-closure assay, the transmigration of vectortransfected L cells on hyaluronan was reduced to background levels by the inclusion of the KM201 antibody in the assay. This independent assay demonstrated that the transmigration rates of both the GA CD44-expressing and the EE CD44-expressing cells were the same as those of cells transfected with vector alone, and that these background levels of migration were unaffected by the E1/2 antibody.
Discussion
Aberrant expression or overexpression of CD44 in cells can result in the acquisition of a metastatic phenotype [18] [19] [20] . Where it has been examined, the interaction between CD44 and hyaluronan has been shown to be an essential component of this process [21, 22] . Given the multistep nature of metastatic progression, it is important to discriminate between mechanisms that regulate cell adhesion and those that regulate cell migration.
It is clear that the ability of CD44 to bind hyaluronan is strictly regulated and that this regulation can occur at a number of levels. In addition to cells that constitutively bind hyaluronan, it is known that some CD44-positive cells cannot bind ligand unless induced to do so by multivalent activating monoclonal antibodies. This activation can occur at 4°C and with paraformaldehyde-fixed cells, which suggests that these antibodies act by modulating cell-surface distribution rather than by indirectly triggering intracellular signalling pathways [3] . However, as these antibodies do not stimulate hyaluronan binding in all CD44-positive nonbinding cells, other regulatory mechanisms, such as modulation of glycosylation [7, 8] , must clearly play a part. In addition, the ability of CD44 to interact with ligand may critically depend on how the hyaluronan is presented. For example, although removal of the cytoplasmic domain of CD44 prevents it from binding to soluble FITC-conjugated hyaluronan [9, 11, 12, 17] it can still mediate cell adhesion to hyaluronan-coated plates, albeit with a significantly lower efficiency than wild-type CD44 [5, 9] . One interpretation of these data is that, when immobilized, hyaluronan can stabilize CD44 clusters, thereby at least partly overcoming receptor destabilization resulting from loss of the cytoplasmic domain. Such an interpretation is supported by data demonstrating that the CD44 protein without the cytoplasmic domain can be induced to bind to soluble hyaluronan either by incubation with an activating monoclonal antibody or by dimerization of the transmembrane domain [17] .
The mechanism by which the cytoplasmic domain might stabilize receptor clustering is unknown. Lokeshwar et al. [10] have demonstrated a requirement for the proposed ankyrin-binding domain (between Asn304 and Leu318) but Perschl et al. [17] have created deletions within this domain without impairing hyaluronan binding capacity. Whether there is a specific inside-out signalling mechanism or a more generalized sequence-independent role for the cytoplasmic domain is not known. The data presented here indicate that phosphorylation of Ser323 and/or Ser325 is not required. As discussed in full elsewhere [12] , there is a discrepancy between these results and those of Puré et al. [11] who reported that equivalent mouse phosphorylation mutants exhibited a reduced hyaluronan-binding capacity. Of relevance to this discrepancy are the studies of Lokeshwar et al. [10] and Perschl et al. [17] , who have demonstrated that premature truncation of the cytoplasmic domain of CD44 (at Leu318 or Gly305, respectively), which removes the target serine residues, does not impair ligand binding. By contrast, our data would suggest that phosphorylation plays a crucial role in outside-in signalling whereby an interaction with extracellular ligand stimulates enhanced cell migration. In order for a cell to migrate there must be an interaction between the matrix and a transmembrane receptor resulting in a cytoskeletal reorganization; these events must be dynamic and involve the coordination of a number of physical and/or signalling processes [23, 24] . Changes in the cytoskeletal distribution could result from a direct interaction between CD44 and intracellular structural components, in a manner similar to that by which the ␤ 1 integrin subunit binds to ␣-actinin and talin [25, 26] , which link the integrin to the actin microfilaments. Consistent with this idea are the membrane mobility studies of Jacobson et al. [27, 28] , where CD44 was shown to exhibit a restricted mobility in fibroblasts, with a more rapid redistribution at the leading edge than at the trailing edge of motile cells. These data suggest that CD44 transiently interacts with the cytoskeleton. Studies to identify CD44-associated cytoskeletal components have been complicated by the demonstration that although 30-80 % of the CD44 remains associated with the detergent-insoluble cytoskeletal fraction of migratory cells, this insolubility is independent of the cytoplasmic domain and reflects a function of the transmembrane domain, which probably associates with Triton X-100-insoluble lipids [29] [30] [31] .
Other approaches to identifying a direct association between CD44 and the cytoskeleton have led to reports that CD44 binds to ankyrin [10] and to members of the ERM (ezrin, radixin and moesin) family [32] . The physiological relevance of these interactions and the role of CD44 phosphorylation in their regulation remains to be determined.
In addition to (or instead of) a mechanical interaction, it is possible that CD44 phosphorylation effects cytoskeletal reorganization indirectly by the activation of a signalling pathway. Precedents for such a mechanism arise from studies with integrins [33] . Clustering of integrins activates the focal adhesion kinase resulting in autophosphorylation and the phosphorylation of a number of other focal adhesion components, including paxillin and tensin. These components are then primed to interact with key components of intracellular signaling pathways that contain phosphotyrosine-binding SH2 domains; these interactions ultimately result in cytoskeletal reorganization. More recently, the discovery of an integrin-associated serine/threonine kinase that can phosphorylate the cytoplasmic domain of ␤1 integrin has suggested that there is an additional signaling pathway [34] . Overexpression of the kinase results in reduced cell adhesion and increased anchorage-independent growth. In order to determine the mechanisms by which CD44 phosphorylation regulates cell migration, it will first be necessary to determine the phosphorylation status of Ser323 and Ser325. We have previously shown that mutation of either residue abolishes CD44 phosphorylation [15] , consequently it is not known whether both serines are phosphorylated or whether one serine acts as part of the kinase consensus site and is therefore required for phosphorylation of the other. It will then be necessary to identify the CD44 kinase and structural or signaling intracellular proteins that can discriminate between the phosphorylated and dephosphorylated receptor.
Conclusions
As previously reported [5] , we demonstrate in this paper that expression of wild-type human CD44 in the CD44-negative RPM-MC melanoma cells results in an enhanced CD44-specific ability of these cells to bind to, and migrate on, a hyaluronan-coated substratum. In order to determine whether binding and migration are regulated separately, we extended these studies to look at two different CD44 phosphorylation mutants and found that they retain the ability to bind soluble and matrix-associated hyaluronan but cannot support CD44-dependent migration on hyaluronancoated plates, or through hyaluronan-coated Transwell filters. This is not a cell-type specific event as similar results are obtained using transfected L-cell fibroblasts. These studies demonstrate a distinct mechanism for the control of CD44-dependent cell migration, which is considered to be a critical component in tumour progression and metastatic spread.
Materials and methods

Generation and characterization of transfected cell lines
The CD44 phosphorylation mutants, in which Ser323 and Ser325 of the haematopoietic form of human CD44 were changed to Gly323 and Ala325 (GA CD44) or to Glu323 and Glu325 (EE CD44), were expressed from their respective cDNAs subcloned into the pSRa-neo eukaryotic expression vector, as previously described [12, 15] . RPM-MC melanoma cells and L-cell fibroblasts cultured on 60 mm tissue culture dishes were transfected with pSRa-neo vector alone, or vector expressing wild-type CD44 or CD44 phosphorylation mutants using the Cell Phect Transfection kit (Pharmacia). After 16 h, cells were transferred to 150 mm dishes containing Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % fetal calf serum (FCS) and 0.5 mg ml -1 G418. After 10-14 days, G418-resistant single colonies were isolated and analysed by immunofluorescence for human CD44 expression using the E1/2 monoclonal antibody [13] . Throughout these studies independent transfected lines were continuously monitored for human and murine CD44 expression by ELISA assay as follows: cells were seeded at 8 × 10 3 cells per well in 96-well plates (Falcon) cultured overnight, fixed with 3 % paraformaldehyde and incubated sequentially with the E1/2 or KM201 monoclonal antibodies (25 g ml -1 ) and HRPconjugated anti-mouse or anti-rat immunoglobulin (Vector Laboratories). The reaction was visualized using the soluble peroxidase substrate, ophenylenediamine dihydrochloride (OPD; Sigma).
Hyaluronan binding
To measure adhesion to a hyaluronan substratum, 96-well tissue culture plates were incubated for 32 h at 4°C with 75 l of 5 mg ml -1 Streptococcal hyaluronan (Calbiochem) per well. An equal volume of 2 % BSA was then added and the plates left for a further 16 h. Control wells were incubated with a 1 % BSA solution only. All plates were washed three times in DMEM containing 10 % FCS and used immediately. Cells were detached from subconfluent cultures by incubation for 5 min in a solution containing 0.25 % trypsin (Sigma) and 0.02 % EDTA and allowed to recover in DMEM containing 10 % FCS for 1 h in 90 mm petri dishes (Sterilin). Cells (1.5 × 10 4 ) were added to triplicate wells and allowed to adhere for 30 min at 37°C. Non-adherent cells were removed by washing three times in DMEM containing 10 % FCS. To determine the number of adherent cells, cells were fixed in 3 % paraformaldehyde for 15 min, permeabilized in -20°C methanol for 4 min, washed twice in PBS and 50 l of 0.5 % crystal violet added for 15 min followed by a final two washes in PBS. Dye was eluted from cells with 50 l of 10 % acetic acid and absorbance read at 595 nm. Where indicated, 400 g ml -1 of the E1/2 antibody was included in the 1 h recovery period. To measure binding of FITC-conjugated hyaluronan, cells were detached in 70 mM ice-cold EDTA and flow cytometry and data analysis performed as previously described [12, 17] .
Migration assays
For wound-healing assays, 24-well tissue culture plates (Falcon) were hyaluronan-coated as described above. RPM-MC or L-cell lines were seeded at 1.75 × 10 5 or 2.5 × 10 5 cells per well, respectively, and cultured overnight in DMEM containing 10 % FCS. Wounds of approximately 0.6 mm (L cells) or 1.2 mm (RPM-MC cells) were gently scored in the monolayers using a Gilson tip, the monolayers washed and the wound width measured at four separate points using a graticule. Closure was monitored at 24 and 48 h. Where indicated, 400 g ml -1 of the E1/2 antibody was present during the migration assay and replaced every 24 h. For Transwell migration assays, 24 mm polycarbonate Transwell filters (8 m Costar) were coated with hyaluronan or BSA as described above. Cells (1.5 × 10 4 ) were seeded onto the filter and cultured for 48 h in DMEM containing 10 % FCS. After 48 h, the number of cells that had migrated through the filter was determined.
Filters were fixed and stained as described above. Cells on the upper face of the filter were then removed by scraping, and the dye in the cells on the lower face (migrated cells) was eluted in 50 l of 10 % acetic acid and the absorbance read at 595 nm. Where indicated, 400 g ml -1 of the E1/2 antibody was added at the time of seeding and replaced every 24 h.
